The early biomarker of tumor chemosensitivity, KELIM (The modeled CA-125 ELIMination rate constant K), has been validated for patients with stage III or IV HGSC treated with adjuvant carboplatin-paclitaxel regimen and is calculated with the CA125 longitudinal kinetics during the first 100 chemotherapy days (59). This evidence concerns the gene MUC16 and neoplasm.